Oxiracetam In The Treatment Of Multi-infarct Dementia And Primary Degenerative Dementia

Effect None
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 73
Sex Both Genders
Age Range 65+
Notes for this study:
In persons with primary or multiinfarct dementia supplemented with oxiracetam, there appeared to be a significant reduction in symptoms of cognitive decline with particular improvement of verbal learning (word fluency) although a functional assessment (Instrumental Activities of Daily Living Scale) showed no significant changes.